前立腺肥大症症例に対するα1ブロッカーによる射精障害の検討 - 塩酸タムスロシンとナフトピジルの比較 -

Abstract

前立腺肥大症88例を, 内服薬剤別に塩酸タムスロシン40例とナフトピジル48例で分け, 薬剤による射精障害の頻度及びQOLへの影響を比較検討した.その結果, 年齢及び投与期間と, 射精障害の有無による投与前後の排尿パラメーターに有意差は見られなかった.投与前の前立腺重量と残尿量と, 服用後の射精障害の頻度は塩酸タムスロシン群の方が高い傾向が見られた

We cross-sectionally studied the incidence and impact on quality of life of ejaculatory disorders caused by alpha-1 adrenoceptor antagonists (tamsulosin or naftopidil) in patients with benign prostatic hyperplasia (BPH). By questionnaire, we queried 88 clinical BPH patients concerning ejaculatory disorders, who were treated with tamsulosin or naftopidil between February 1999 and August 2003. We investigated the difference in the incidence and types of disorders between the two drugs. Of the 88 patients, 63 (71.6%) had sexual activities during the treatment. The incidence of ejaculatory disorders was significantly higher in the tamsulosin group (30.0%) than in the naftopidil group (3.0%). Eighty percent of patients having the disorders noticed the absence or reduced volume of semen although they experienced orgasms. The median quality of life index concerning the disorder was rated as 4, "mostly dissatisfied." Our results indicated that ejaculatory disorders occurred more frequently in the tamsulosin group. We should inform patients about this adverse effect caused by alpha-1 adrenoceptor antagonists prior to treatment.